Chai Discovery (@chaidiscovery) — Twitter Score 24 out of 1000

Chai Discovery is an AI molecular design and drug discovery company that builds models for biological structure reasoning, molecular generation, and pre-clinical drug discovery. Chai Discovery's Twitter Score is 24 out of 1000 as of August 2026, ranking #40,931 (top 10%) among 483,944 tracked accounts.

Chai Discovery was co-founded by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud, with Meier serving as CEO. The company was established in 2024 and has since built a suite of foundation models targeting drug discovery workflows. Its first model, Chai-1, focuses on molecular-structure prediction and was released alongside the company's seed financing announcement. Chai-2 followed as a zero-shot generative platform for fully de novo antibody design, reporting double-digit experimental success rates. Chai-3, the company's most recent model, was announced alongside its Series C in July 2026.

Chai Discovery has raised successive funding rounds at a rapid pace. An approximately $30 million seed round led by Thrive Capital, OpenAI, and Dimension Capital was announced in September 2024. A $70 million Series A led by Menlo Ventures followed in August 2025, and a $130 million Series B from General Catalyst and Oak HC/FT was announced in December 2025. In July 2026, Chai Discovery announced a $400 million Series C at a $3.8 billion valuation, led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension.

Chai Discovery is affiliated with pharmaceutical partners including Eli Lilly and Company, Pfizer, Novartis, and argenx. Chai Discovery's account has published 95 posts and has been mentioned by 45 accounts a total of 81 times.

Who follows Chai Discovery on X?

The accounts that follow Chai Discovery include 88 founders, 33 angel investors, 26 influencers and 8 VCs. Among them are Kyle Samani, Fred Ehrsam, Tarun Chitra, Vance Spencer, Zmanian and Olaf.